Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, double-blind, placebo-
about
Systematic literature review and meta-analysis of the efficacy and safety of prescription opioids, including abuse-deterrent formulations, in non-cancer pain managementStrategies to prevent opioid misuse, abuse, and diversion that may also reduce the associated costs.Opioid formulations with sequestered naltrexone: a perspective review.Effects of concurrent intravenous morphine sulfate and naltrexone hydrochloride on end-tidal carbon dioxideStrategies to reduce the tampering and subsequent abuse of long-acting opioids: potential risks and benefits of formulations with physical or pharmacologic deterrents to tampering.Designing opioids that deter abuseAbuse-deterrent formulations, an evolving technology against the abuse and misuse of opioid analgesics.Impact of intravenous naltrexone on intravenous morphine-induced high, drug liking, and euphoric effects in experienced, nondependent male opioid users.Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users.Abuse Potential with Oral Route of Administration of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users.Morphine sulfate and naltrexone hydrochloride extended release capsules for the management of chronic, moderate-to-severe pain, while reducing morphine-induced subjective effects upon tampering by crushing.Current approaches in tamper-resistant and abuse-deterrent formulations.Abuse-deterrent and tamper-resistant opioids: how valuable are novel formulations in thwarting non-medical use?Assessment of extended-release opioid analgesics for the treatment of chronic pain.Current topics in opioid therapy for pain management: addressing the problem of abuse.Sequestered naltrexone in sustained release morphine or oxycodone - a way to inhibit illicit use?Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulations.The role of abuse-deterrent formulations in countering opioid misuse and abuse.Abuse-Deterrent Opioid Formulations: Pharmacokinetic and Pharmacodynamic Considerations.Abuse-deterrent formulations of prescription opioid analgesics in the management of chronic noncancer pain.Experience with an extended-release opioid formulation designed to reduce abuse liability in a community-based pain management clinic.Determining the clinically important difference in visual analog scale scores in abuse liability studies evaluating novel opioid formulations.Opioid titration and conversion in patients receiving morphine sulfate and naltrexone hydrochloride extended release capsules.Morphine sulfate and naltrexone hydrochloride extended release capsules in patients with chronic osteoarthritis pain.The implications of tamper-resistant formulations for opioid rotation.Intravenous abuse potential study of oxycodone alone or in combination with naltrexone in nondependent recreational opioid users.Abuse Potential Study of ALO-02 (Extended-Release Oxycodone Surrounding Sequestered Naltrexone) Compared with Immediate-Release Oxycodone Administered Orally to Nondependent Recreational Opioid Users.Assessment of pharmacodynamic effects following oral administration of crushed morphine sulfate and naltrexone hydrochloride extended-release capsules compared with crushed morphine sulfate controlled-release tablets and placebo in nondependent recrAbuse-deterrent opioids: an update on current approaches and considerations.Effects of ethanol on the pharmacokinetics of extended-release oxycodone with sequestered naltrexone (ALO-02).
P2860
Q26853312-45AD7325-59AB-40D8-83F7-98B088980EE2Q33932344-8AAF7E49-AB3C-4E79-8FA1-5ED1AA61100CQ33949447-81D9A659-3154-4EE5-863E-7543A4BBC50AQ35925351-2741561A-59B1-4227-8D99-B9A8DE23B670Q36399627-20F14F30-EABA-417A-A4DE-7B2C15270DDCQ36415568-B569F44E-C12B-473E-91FF-73CAE1E85FDFQ36549049-607076EA-86D8-4F5D-B486-E9DA9A4EE620Q36649920-3A0806A8-2469-4FE7-8E08-F8C9FCDC19E4Q37265572-43CA6DC9-EDB6-428F-ACA4-CC8F7EACF6F2Q37616572-708AB141-1D77-458B-9C5C-EB8AE90AADE5Q37862258-E6AC08E5-AA91-44E0-9B64-6FED8C1C9DB0Q38005778-F47B3A0A-8501-4AB3-88E3-607416FF1ABBQ38068507-03A8BCAE-C2CC-4F50-9F73-215B179CED02Q38092855-91BE2B60-1FF0-4C05-9295-3FF1C4D06B5DQ38112360-E9D09A3B-F584-44C9-8484-989775BEDC4BQ38160935-D71503B6-A4CC-4275-96C1-13F6728449D5Q38632934-A050B579-4B32-4AFE-AC8E-5212A796D711Q38643510-904CC268-E214-4BFB-8B15-E370D3FC6466Q38683620-E43ACB32-2199-49F9-92F8-A99A32F79164Q38799636-E838BB0F-56F7-465A-8038-4832C65C8385Q38905036-7ECC0D2C-1334-4FCC-8420-77ABD78AB2A9Q39901255-980DF97D-81C2-4DF3-9644-24AEF2796669Q42615758-FC7DEB64-E108-4229-8ED3-03FEE73E36B0Q42950103-E1D56D47-249B-49D0-B43A-E34FD34EE321Q44336529-2710A21C-0915-40D3-B719-129365887EB8Q44337403-EB4B756F-8A3E-468C-86F8-9F918BB46349Q44339589-4E023FF9-4301-497D-984C-FD849D46B310Q44339796-2296E29E-354F-4398-9A9E-98E5E363216BQ47274936-3E3B3996-91DD-4811-9525-46C3B89087F8Q51307265-4D77DE3F-1855-462E-B015-AFC45C032584
P2860
Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, double-blind, placebo-
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Subjective effects and safety ...... omized, double-blind, placebo-
@en
Subjective effects and safety ...... omized, double-blind, placebo-
@nl
type
label
Subjective effects and safety ...... omized, double-blind, placebo-
@en
Subjective effects and safety ...... omized, double-blind, placebo-
@nl
prefLabel
Subjective effects and safety ...... omized, double-blind, placebo-
@en
Subjective effects and safety ...... omized, double-blind, placebo-
@nl
P2093
P921
P1476
Subjective effects and safety ...... omized, double-blind, placebo-
@en
P2093
Beatrice Setnik
Franklin Johnson
Joseph Stauffer
Marta Sokolowska
Myroslava Romach
P304
P356
10.2165/11530800-000000000-00000
P577
2009-01-01T00:00:00Z